Cetera Investment Advisers Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Cetera Investment Advisers grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 232,598 shares of the company's stock after buying an additional 5,806 shares during the quarter. Cetera Investment Advisers' holdings in Eli Lilly and Company were worth $179,565,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in LLY. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $8,407,908,000. Proficio Capital Partners LLC increased its position in Eli Lilly and Company by 100,387.1% in the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after buying an additional 5,197,038 shares during the period. Wellington Management Group LLP lifted its stake in Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares during the last quarter. Capital International Investors boosted its holdings in shares of Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after acquiring an additional 1,645,222 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $1,240,653,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on LLY shares. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. Finally, Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,002.80.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Trading Down 0.2 %

Eli Lilly and Company stock opened at $821.66 on Tuesday. The company has a 50 day moving average price of $823.48 and a 200 day moving average price of $814.29. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The firm has a market capitalization of $779.07 billion, a price-to-earnings ratio of 70.17, a P/E/G ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the firm posted $2.58 earnings per share. The firm's quarterly revenue was up 45.2% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. Eli Lilly and Company's payout ratio is presently 51.24%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.